Galectin Therapeutics (GALT) Profit After Tax (2010 - 2026)

Galectin Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$5.0 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 47.61% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at -$26.3 million (up 41.91% YoY), while the FY2025 annual figure was -$30.8 million, up 34.46% from the prior year.
• Profit After Tax for Q1 2026 stood at -$5.0 million, up from -$5.5 million in the prior quarter.
• The five-year high for Profit After Tax was -$5.0 million in Q1 2026, with the low at -$12.4 million in Q2 2024.
• The 5-year median for Profit After Tax is -$9.9 million (2022), against an average of -$9.6 million.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax sank 56.71% in 2022, then jumped 54.04% in 2025.
• Galectin Therapeutics' Profit After Tax stood at -$10.6 million in 2022, then advanced by 5.99% to -$10.0 million in 2023, then declined by 19.71% to -$12.0 million in 2024, then surged by 54.04% to -$5.5 million in 2025, then climbed by 8.25% to -$5.0 million in 2026.
• Business Quant data shows GALT's Profit After Tax at -$5.0 million in Q1 2026, -$5.5 million in Q4 2025, and -$8.2 million in Q3 2025.